Antiva Biosciences, Inc.
Menlo Park
California
United States
9 articles about Antiva Biosciences, Inc.
-
Antiva Biosciences Strengthens Leadership with Key New Appointments
10/19/2023
Antiva Biosciences today announced several key new appointments designed to strengthen the company's leadership as it continues to advance its lead development candidate, ABI-2280.
-
Antiva Biosciences Closes $53 Million Series E Equity Financing Led by MPM-BioImpact Capital and Names Kristine Ball President and CEO
4/27/2023
Antiva Biosciences today announced the closing of a $53 million Series E equity financing.
-
Antiva Biosciences Named Winner of Global Women's HealthTech Award By World Bank Group and Consumer Technology Association
1/6/2022
Honor Recognizes Companies Advancing Innovative Solutions to Improve Women's Health and Safety in Emerging Markets.
-
Antiva Biosciences Closes $31 Million Series D Equity Financing
11/2/2021
Antiva Biosciences today announced the closing of a $31 million Series D equity financing.
-
Gail Maderis, currently president and chief executive officer of South San Francisco-based Antiva Biosciences, has a rock-solid resume.
-
In the biotech world, only 7 to 9 percent of companies have women as their chief executives. Antiva BioSciences is a good example of how this problem is perpetuated.
-
Antiva Biosciences Closes $15 Million Series C-1 Financing
7/10/2018
Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, has raised $15 million in Series C-1 financing led by Hillhouse Capital Management.
-
Bay Area's Antiva Grabs $22 Million Series C For HPV Therapy
3/28/2017
-
Chimerix Founder's Antiva Nabs $16 Million and Taps Longtime Biotech Exec as New CEO
8/6/2015